Puma Biotechnology, Inc.

NASDAQ:PBYI

2.81 (USD) • At close December 23, 2024
Bedrijfsnaam Puma Biotechnology, Inc.
Symbool PBYI
Munteenheid USD
Prijs 2.81
Beurswaarde 137,936,437
Dividendpercentage 0%
52-weken bereik 2.23 - 7.73
Industrie Biotechnology
Sector Healthcare
CEO Mr. Alan H. Auerbach
Website https://www.pumabiotechnology.com

An error occurred while fetching data.

Over Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in

Vergelijkbare Aandelen

PAVmed Inc. logo

PAVmed Inc.

PAVM

0.645 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

2.03 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.15 USD

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

4.74 USD

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

1.11 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.838 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

0.775 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

14.13 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)